Finally, the APEX trial randomizes patients with EGFR mutant stage II-IIIA NSCLC following complete tumor resection, to evaluate the efficacy and safety of almonertinib, a third-generation EGFR TKI targeting both EGFR-sensitizing and T790M resistance mutations, combined with or without chemotherapy (NCT04762459). Here, EGFR is linked to neoplasm.